Press release
Oct 7, 2016

Sosei Subsidiary Heptares Therapeutics wins UK Best Established Biotech Company Award at OBN Annual Awards 2016

Tokyo, Japan –7 October 2016: Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565) today announces Heptares Therapeutics (“Heptares”), the wholly-owned subsidiary of Sosei, has been announced as the winner of the Best Established Biotech Company Award at the OBN Annual Awards ceremony celebrating outstanding achievement in the UK life sciences sector, held last night in Oxford, UK. The award was presented to Malcolm Weir, Founder and CEO of Heptares, and Executive Vice President and Chief R&D Officer of Sosei.

Heptares received the award in recognition of its outstanding success during the 18 months since its acquisition by Sosei Group in February 2015. This success is highlighted by four partnerships signed with major pharmaceutical companies around its pipeline and technology (Allergan, AstraZeneca, Pfizer and Teva), as well as significant R&D progress. These deals have been transformational for Heptares (and Sosei), providing expertise and resource for its partnered pipeline, validation for its approach and industry leading platform and substantial financial resources to drive its growth strategy forwards, including the advancement of its in-house R&D pipeline.

This award was judged by a panel of leading figures from the UK life sciences industry.

OBN is the membership organisation supporting and bringing together the UK’s emerging life sciences companies, corporate partners and investors.